Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
about
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53Finding the needle in the haystack: why high-throughput screening is good for your health.Targeting Oncogenic Mutant p53 for Cancer TherapyTargeting the Checkpoint to Kill Cancer CellsCurrent and future trials of targeted therapies in cutaneous melanomaChanges in oscillatory dynamics in the cell cycle of early Xenopus laevis embryosCancer's Achilles' Heel: Apoptosis and Necroptosis to the RescueFine tuning the cell cycle: activation of the Cdk1 inhibitory phosphorylation pathway during mitotic exit.Mitotic progression becomes irreversible in prometaphase and collapses when Wee1 and Cdc25 are inhibitedMitotic trigger waves and the spatial coordination of the Xenopus cell cycle.High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients.Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line.Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2.In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinaseTargeting p53 for Novel Anticancer Therapy.Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53.WEE1 inhibition sensitizes osteosarcoma to radiotherapyNew insights into checkpoint kinase 1 in the DNA damage response signaling network.Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapyInfluence of cell cycle checkpoints and p53 function on the toxicity of temozolomide in human pancreatic cancer cells.Genistein abrogates G2 arrest induced by curcumin in p53 deficient T47D cellsTargeting lung cancer through inhibition of checkpoint kinases.Genetic inhibition of the atypical kinase Wee1 selectively drives apoptosis of p53 inactive tumor cellsEfficient induction of apoptosis by wee1 kinase inhibition in hepatocellular carcinoma cells.MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.Targeting cell cycle regulators in hematologic malignancies.The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in GlioblastomaRadiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor.Analytical Validation of AmpliChip p53 Research Test for Archival Human Ovarian FFPE Sections.p53 mediates interstitial cystitis antiproliferative factor (APF)-induced growth inhibition of human urothelial cellsIdentification of Phosphorylated Cyclin-Dependent Kinase 1 Associated with Colorectal Cancer Survival Using Label-Free Quantitative Analyses.Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome.Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma.A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.Molecular targets and mechanisms of radiosensitization using DNA damage response pathways.Wee1 kinase as a target for cancer therapy.Strategies for optimizing the response of cancer and normal tissues to radiation.
P2860
Q24657532-B3656C71-DF24-4A95-AAD2-4DCD7E66F703Q24802613-69206645-9681-42F9-BDE3-B2178BA7876DQ26770856-2952C04A-51D3-463A-AF42-F4D32D75A291Q26795781-94D4649A-2523-46F0-9107-A8DB7461D02AQ27022355-0A90B61C-045E-48F3-A8F8-0555D4FCB094Q27315970-481B0D29-117F-491B-B96A-3876F357B5C7Q28066868-C5326717-5080-4999-829F-938ECC889F8DQ30439662-CE36E68A-C890-47A0-B518-93ABA9DEFA60Q30499682-444E63DA-1A45-4ADC-8A3E-E7D2CF6549E9Q30543867-5305EFFB-CCF5-4771-8C1D-139D8AC293F5Q31119438-14FA2852-A95E-4503-8612-239441E554BCQ33267031-52575559-5123-4DF4-9A0A-FCA664B822A1Q33369696-0400E010-43FB-43DE-A762-76D99EF2AB84Q33557673-28DD5E30-CBB9-42EC-99C6-C94884B1CE51Q33655329-7D6DFB06-3D64-47C6-81C9-4C7F7C3619B9Q33697172-B8696D65-CE43-4AFE-83EC-9A88C9EBD3ADQ33884881-6AA4E3B1-9917-4D03-8987-8F211ABF7E17Q34129155-A82DF81D-A3C0-45D1-AC1F-A21BAD8D6AA3Q34293078-8C933948-9EF9-4972-ABCF-B4D894B718AEQ34311842-0494E815-0685-4967-8DA7-C58F09E89DEFQ34354462-CD0E340B-9883-481E-98E5-453CF3AA1084Q34564108-D4F00C76-2542-4844-A617-DFEAE7DFA596Q35128547-65357D2C-3398-455F-93F2-8C7025E22783Q35187926-0BEAF70F-9727-4E3B-B55B-3DE0100BC084Q35194021-75906EC5-482A-4E1C-8977-816C3D368573Q35196526-47239285-EAD5-4024-9B98-F9C80B4D4312Q35334436-4BCC9290-A162-4BC8-9BB7-98CCEDA6A3B5Q35463482-3B72549C-410A-4BA7-B7A8-041806EC4EB7Q35653286-2EDDB0BF-8341-4549-9706-F6F412B5E96AQ35678565-714A9E80-3F47-4359-8BFF-7F5214E59CBCQ35925185-0BEB4862-C963-4220-8526-E59217980AAEQ36069009-2B50FE6D-18D6-460D-93FC-1C9F10C65148Q36244669-87DD58C7-C238-4570-A7A0-C6F64E289F6BQ36291648-8D5E72CD-09BF-41D9-9D90-A912126BA85AQ36545022-F39CFA1C-2FF2-40B9-B7CD-CE189BF762F4Q36738836-A924046B-05A0-4F5E-AF3F-B5ADC472D23EQ36750123-7B0A1D24-3A40-4F4A-A424-0C06C5A1A500Q36792626-A30BCE18-BE36-4940-9350-818E1D846543Q37396839-9B69D90D-B656-4AE5-8C6A-B6011ABB7F1BQ37531724-3D908ED1-4F50-4FE0-9DCB-B98CAF45C261
P2860
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
@ast
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
@en
type
label
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
@ast
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
@en
prefLabel
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
@ast
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
@en
P2093
P1433
P1476
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator
@en
P2093
Lawrence T
Leopold WR
P304
P407
P577
2001-11-01T00:00:00Z